胃部・食道胃接合部腺癌市場:ヨーロッパ主要国の治療薬市場...市場調査レポートについてご紹介

【英文タイトル】Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/Targets of Interest
3.2 Staging
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening
4.1.2 Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 France
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
4.3 Germany
4.3.1 Screening and Diagnosis
4.3.2 Clinical Practice
4.4 Italy
4.4.1 Screening and Diagnosis
4.4.2 Clinical Practice
4.5 Spain
4.5.1 Screening and Diagnosis
4.5.2 Clinical Practice
4.6 UK
4.6.1 Screening and Diagnosis
4.6.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 HER2-Targeted Therapy
5.2.1 Herceptin (trastuzumab)
5.3 Angiogenesis Inhibitors
5.3.1 Cyramza (ramucirumab)
5.3.2 Aitan (apatinib)
5.4 Chemotherapies
5.4.1 TS-1 (tegafur, gimeracil, oteracil)
5.4.2 Abraxane (nab-paclitaxel)
6 Unmet Need and Opportunity
6.1 Overview
6.2 First-Line Therapy for HER2-Negative Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 New Molecular Targets for Targeted Therapies
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Perioperative and Postoperative Therapies
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 More Efficacious HER2-Targeted Therapies
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Peritoneal Metastases
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Better Clinical Trial Design
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Phase III Clinical Development
7.3 HER2-Targeted Therapies
7.3.1 Kadcyla (T-DM1; trastuzumab emtansine)
7.3.2 Perjeta (pertuzumab)
7.4 Immune Checkpoint Inhibitors
7.4.1 Keytruda (pembrolizumab)
7.4.2 Opdivo (nivolumab)
7.5 Further Strategies for G/GEJAC Treatment
7.5.1 Napabucasin
7.5.2 Lynparza (olaparib)
7.5.3 Nimotuzumab
7.5.4 TAS-118
7.6 Early/Near-Phase III Pipeline Drugs
7.6.1 GS-5745
7.6.2 Masitinib
7.7 Promising Drugs in Early-Stage Development
7.7.1 Immune Checkpoint Inhibitors
7.7.2 MET-Targeting Drugs
7.7.3 Antibody-Drug Conjugates
7.8 Biosimilars
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers – France
8.1.4 Drivers and Barriers – Germany
8.1.5 Drivers and Barriers – Italy
8.1.6 Drivers and Barriers – Spain
8.1.7 Drivers and Barriers – UK
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed G/GEJAC Patients
9.4.2 Percent of Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research – Key Opinion Leaders Interviewed for this Report
9.6 Primary Research – High-Prescriber Survey
9.7 About the Authors
9.8 About GlobalData
9.9 Disclaimer


【レポート販売概要】

■ タイトル:胃部・食道胃接合部腺癌市場:ヨーロッパ主要国の治療薬市場
■ 英文:Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024
■ 発行日:2015年12月9日
■ 調査会社:GlobalData
■ 商品コード:GDHC291CFR
■ 調査対象地域:ヨーロッパ
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。